GSK's Mo-Rez shows promise in ovarian and womb cancer trials

GSK reports that its drug Mo-Rez shows promising results in treating gynaecological cancers, shrinking or eliminating tumours in 62% of ovarian cancer patients and 67% of endometrial cancer patients in early trials. The company aims to accelerate the drug's development as it seeks to become a blockbuster treatment.

Read the full story at The Guardian AU→